Apellis Pharmaceuticals - APLS Stock Forecast, Price & News

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APLS shares.
View APLS analyst ratings or view top-rated stocks.

14 brokers have issued 1 year price targets for Apellis Pharmaceuticals' shares. Their APLS share price forecasts range from $40.00 to $139.00. On average, they expect the company's stock price to reach $78.40 in the next twelve months. This suggests a possible upside of 24.3% from the stock's current price.
View analysts price targets for APLS or view top-rated stocks among Wall Street analysts.

Apellis Pharmaceuticals' stock was trading at $51.71 at the beginning of the year. Since then, APLS shares have increased by 21.9% and is now trading at $63.05.
View the best growth stocks for 2023 here.

Apellis Pharmaceuticals saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 10,740,000 shares, an increase of 18.5% from the February 13th total of 9,060,000 shares. Based on an average daily volume of 1,450,000 shares, the short-interest ratio is currently 7.4 days.
View Apellis Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our APLS earnings forecast.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced its earnings results on Tuesday, February, 21st. The company reported ($1.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.45) by $0.05. The company had revenue of $22.70 million for the quarter, compared to analysts' expectations of $24.44 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 204.77% and a negative net margin of 864.70%. Apellis Pharmaceuticals's revenue was down 62.4% compared to the same quarter last year.

ETFs with the largest weight of Apellis Pharmaceuticals (NASDAQ:APLS) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC), First Trust Innovation Leaders ETF (ILDR), Harbor Health Care ETF (MEDI), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3X Shares (LABU), Jacob Forward ETF (JFWD) and Invesco Nasdaq Biotechnology ETF (IBBQ).

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

(APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Apellis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Avoro Capital Advisors LLC (9.61%), T. Rowe Price Investment Management Inc. (5.28%), Price T Rowe Associates Inc. MD (2.49%), Jennison Associates LLC (2.27%), Geode Capital Management LLC (1.58%) and Boxer Capital LLC (1.43%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Pascal Deschatelets, Victoria L Brown and Victoria L Brown.
View institutional ownership trends.

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APLS stock can currently be purchased for approximately $63.05.

Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $7.02 billion and generates $75.42 million in revenue each year. The company earns $-652,170,000.00 in net income (profit) each year or ($6.13) on an earnings per share basis.

The company employs 476 workers across the globe.

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for the company is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com.